Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

A Rare Case of Therapy-Related B-Cell Acute Lymphoblastic Leukemia Arising From Acute Myeloid Leukemia

A Rare Case of Therapy-Related B-Cell Acute Lymphoblastic Leukemia Arising From Acute Myeloid Leukemia

Authors: Ravikumar V, Berkowitz J, Khan O, Garcia DP, Ratnasabapathy R

Citation: Cureus. 2023 Sep 21;15(9):e45745. doi: 10.7759/cureus.45745. eCollection 2023 Sep.

Specialties: Oncology

 

Related content

Publication
Optical Genome Mapping in Acute Myeloid Leukemia: A Multicenter Evaluation
Publication
NGS defined measurable residual disease MRD after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia
Test FAQ
AML Rapid Mutation Panel
Test FAQ
ABL Kinase Domain Mutation in CML Cell based
On-Demand Webinar
Hemepath Master Class Myeloid Neoplasms MPN MDS AML
On-Demand Webinar
Unwinding with DDX41 A case presentation regarding DDX41 and its germline predisposition to myeloid neoplasms
Audio Podcast
Optimize Oncology Care with Clinical Pathways

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.